gestational%20diabetes%20mellitus
GESTATIONAL DIABETES MELLITUS
Gestational diabetes mellitus (GDM) is any degree of glucose intolerance with onset or first recognition during pregnancy.
Hyperglycemia in pregnancy may be suggested by the presence of glycosuria, a fetus that is large for date, or polyhydramnios.
Overt diabetes mellitus may be found in women presenting with risk factors for type 2 diabetes during the first prenatal visit (before 13 weeks of gestation).

Gestational%20diabetes%20mellitus Management

Monitoring

  • Measure blood pressure, body weight, urinary protein, and check for edema every prenatal visit to detect the development of preeclampsia
  • Regular retinal and renal assessment during pregnancy
  • Monitor urine and/or blood ketones to confirm if diet is adequate
    • Starvation ketosis is common in pregnancy and may have detrimental effects to the fetus
    • Exclude diabetic ketoacidosis in the patient if she is ill or is hyperglycemic
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 3 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 18 hours ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.